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Twitter summary: There is a small risk of cross infection with Pseudomonas aeruginosa in bronchiectasis, 
but the benefit of specialised clinics, chest physiotherapy and pulmonary rehabilitation outweigh 














The risk of cross-infection with pathogens such as Pseudomonas aeruginosa, Methicillin Resistant 
Staphylococcus aureus (MRSA) and Burkholderia cepacia complex, and most recently Mycobacterium 
abscessus is a matter of considerable concern in patients with cystic fibrosis bronchiectasis (CF). (1-4) 
As a result of compelling evidence of transmission of these organisms between people with CF and, in 
the case of P. aeruginosa, the identification of transmissible “epidemic” strains, clear guidance and 
restrictions on contact between CF patients have been introduced.(5,6) CF clinics are segregated, with 
separate clinics for patients with B. cepacia complex infection, P. aeruginosa and other infections. 
Within clinics, any direct contact between individuals with CF is avoided.  In hospital wards, patients in 
most countries will be kept in side rooms separated from other patients, or may be kept on separate 
wards if patients with different infections are hospitalised concurrently.(5,6) CF physicians are also 
advised to practice rigorous hand hygiene and other measures since microorganisms can survive on 
surfaces, hands or clothing for several hours.(4,7) For patient support events and conferences, 
participation by CF patients is heavily restricted. The CF Trust in the UK limits participation strictly to a 
single CF patient for indoor events and has strict regulations for outdoor events. Virtually all 
international guidelines for CF advocate similar measures to reduce the risk of cross-infection.(5,6) 
 
P. aeruginosa transmission is also a potential concern in bronchiectasis not due to CF (henceforth 
referred to as bronchiectasis) because of evidence that P. aeruginosa infection is associated with an 
increased risk of death, exacerbation and worse quality of life.(8) The European Respiratory Society 
(ERS) guidelines for bronchiectasis, published in the European Respiratory Journal in September 2017, 
did not address the issue of cross-infection.(9) This reflects the lack of evidence, which prevents 
recommendations being made in a GRADE based guideline. Of note, the current Spanish Society of 
Pneumology and Thoracic Surgery (SEPAR), the British Thoracic Society and the guidelines from Australia 
and New Zealand also make no specific recommendations regarding the risk of cross-infection.(10-12) 
The ERS guidelines do, however, emphasise the importance of specialised care for the management of 
bronchiectasis, which is best delivered within specialised centres seeing a large number of 
patients.(9,13-15) The ERS guidelines recommend that patients with bronchiectasis and significant 
breathlessness attend pulmonary rehabilitation.(9) Pulmonary rehabilitation and specialist outpatient 
clinics are two environments where patients with bronchiectasis will inevitably come into contact with 
other patients.  
Bronchiectasis has been a neglected condition.(13) This has led, in part, to the development of strong 
patient led advocacy groups. These groups have been a major benefit to the field, aiding in the 
development of clinical guidelines, priority setting, peer support and education.(14-18) Nevertheless, 
meetings involving multiple patients with bronchiectasis represent a further occasion where patients 
will come into direct contact. 
Consequently, as part of the ongoing development of the European Bronchiectasis Multicentre Audit 
and Research Collaboration (EMBARC) and European Lung Foundation (ELF) bronchiectasis patient 
advisory group, we were asked to consider what guidance should be provided to clinicians and patients 
about the risk of cross-infection with bacterial pathogens for patients in clinical practice, or attending 
patient support or academic meetings.   
 
What is the evidence for the risk of cross-infection in bronchiectasis? 
Bronchiectasis and CF are two quite distinct conditions, with a different spectrum of microbiology and a 
different pathophysiology.(17) B. cepacia complex, the most feared transmissible pathogens in CF, is 
very rarely cultured in bronchiectasis. (14-18) While P. aeruginosa is almost universal in CF over a 
patient’s lifetime, P. aeruginosa affects only 20% of patients with bronchiectasis in Europe.(8,15,17,19). 
It may be speculated that only a proportion of patients with bronchiectasis are susceptible to persistent 
P. aeruginosa infection which tends to be concentrated in patients with more severe and extensive 
bronchiectasis.(20)  
We conducted a systematic review using Pubmed (using search terms “cross-infection” OR 
“transmission” AND “bronchiectasis”, supplemented by searches of American Thoracic Society, ERS, BTS 
and World Bronchiectasis Conference abstracts 2014-2017. Searches were limited to articles in English 
only and no date limits were applied). The primary search identified 117 articles, and an additional 8 
abstracts and 4 papers were identified as potentially relevant in supplementary searches. Review of the 
full manuscripts/abstracts excluded 123 articles/abstracts that did not report on cross-infection leaving 
6 potentially relevant articles. These are discussed below.   
Based on this literature review, reports of cross-infection in bronchiectasis to date are extremely rare. 
Acquisition of a multidrug resistant strain of P. aeruginosa in a fourteen-year old boy with bronchiectasis 
due to chronic aspiration was reported by Robinson et al in 2003.(21) The patient had shared 
accommodation and physiotherapy facilities with a CF patient harbouring a genetically identical strain 
making transmission likely.(21) In contrast, a study of 64 P. aeruginosa isolates from 16 patients with 
bronchiectasis in Spain found no evidence of cross-infection, based on the high degree of genetic 
dissimilarity between each isolate.(22)  
De Soyza and colleagues performed a single centre study of 56 isolates and 36 bronchiectasis 
patients.(23) They identified that the vast majority of P. aeruginosa isolates appeared to be acquired 
from the environment but could not exclude cross-infection in two cases. Genetic similarity between 
strains does not prove cross-infection, since acquisition from a common environmental source is also 
possible.(23) A lack of longitudinal “before and after” data also means we do not know if these strains 
represented a new infection by P. aeruginosa, or acquisition of a new strain among many in a patient 
already infected with P. aeruginosa. It is also not known whether any acquisition is associated with a 
clinical deterioration.(23) 
Most recently Hilliam et al performed a multi-centre study using whole genome sequencing of 189 
isolates from 91 patients attending 16 UK bronchiectasis centres.(24) In this study there were 5 
examples of strains from different patients that were genetically similar but again did not have the 
epidemiological or longitudinal data to prove transmission vs common source acquisition. The authors 
concluded that there was no evidence to suggest a widespread transmissible strain in the UK 
bronchiectasis community, and that the P. aeruginosa lineages that are common in bronchiectasis are 
generally those that are also highly abundant in the environment.(24) In a study reported in abstract 
form only, variable number tandem repeat (VNTR) typing was used on 144 isolates from 84 patients 
with bronchiectasis.(25) This study identified 3 cases of bronchiectasis patients infected with 1 x 
Midlands and 2 x Liverpool epidemic strains apparently acquired from CF patients during inpatient stays 
in proximity to CF patients.(25) No evidence of transmission from bronchiectasis patients to other 
bronchiectasis patients was identified. A recently published cohort study from the UK identified 3 
patients sharing strains likely to have been acquired through cross-infection.(26) All three patients were 
known to be chronically infected with P. aeruginosa prior to the presumed acquisition event.(26) Based 
on the apparently infrequent nature of transmission, the authors of this study did not advocate a change 
in infection control policy.(26)  
 
Interpretation 
The above review identifies that cross-infection with P. aeruginosa has occurred in bronchiectasis 
patients but that  
1- Such events are rare, and there is so far insufficient evidence to establish if new acquisition of P. 
aeruginosa infection (vs. acquisition of new strains in patients already infected with P. 
aeruginosa) has occurred. 
2- There is insufficient evidence to show that cross-infection is associated with clinical 
deterioration. 
3- Epidemic and highly transmissible strains have not been identified in the bronchiectasis 
population, except in one study where these were shown to be likely acquired from CF patients. 
4- The strongest evidence for transmission overall and transmission of multidrug resistant or highly 
virulent strains in particular appears to be from CF patients to bronchiectasis patients, rather 
than within the bronchiectasis population. EMBARC data suggests that 10% of bronchiectasis 
patients in Europe are managed in CF clinics, while 45% are managed in centres with shared 
facilities for CF patients.(27)  
5- The current studies are inadequate in terms of numbers of patients and availability of clinical 
data and longitudinal follow-up. There are no studies addressing cross-infection with 
Staphylococcus aureus, MRSA, NTM or less common organisms in bronchiectasis.  
 
Patient perspective 
The EMBARC/ELF patient advisory group discussed this issue with a panel of clinicians at the 2nd World 
Bronchiectasis Conference in Milan, facilitated by the European Lung Foundation. The discussions 
revealed that patients have diverse views on the importance of cross-infection. Patients infected with 
organisms such as P. aeruginosa or S. aureus are concerned about the risk of transmitting this to other 
patients or indeed to immunosuppressed patients and would value guidance on how to reduce any such 
risk. The majority of patients regarded the risk of acquiring new organisms from other patients as small, 
and an acceptable risk if the alternative is a lack of availability of peer support, specialised clinics and 
services such as pulmonary rehabilitation which currently require patients to be together. The majority 
of patients thought they had a right to know about the risks so that they could make an informed 
decision about, for example, attending patient support group events. Many patients expressed concern 
that their condition would be stigmatised if they are required to wear masks or are unable to be in 
contact with others. In general, patients expressed frustration that infection control measures are often 
neglected in terms of their general management. Exacerbations resulting from exposure to relatives, 
members of the public or other patients with viral infections is a more frequent and regular problem for 
patients, and measures to avoid acquiring such infections are rarely discussed with patients.  
 
Recommendations 
Where Bronchiectasis patients are managed within a CF service we suggest managing these patients 
according to the same strict infection control procedures as patients with CF. This includes cohorting 
patients according to their infection status and avoiding contact between patients in both outpatients 
and hospital wards. The same efforts should be made where CF and bronchiectasis patients share 
facilities but do not attend the physical space at the same time. Patients with bronchiectasis should 
avoid sharing outpatient waiting rooms, clinic rooms or hospital bays with patients with CF. For the 
purposes of patient support group meetings, congresses or other events, patients with bronchiectasis 
should not have direct contact with individuals with CF. Detailed guidelines on infection control in 
patients with CF are available from relevant national and international societies.(28) 
Within bronchiectasis clinics, a balance must be found between the theoretical risk of cross-infection, 
and the risk of adversely impacting patient care. Patients with bronchiectasis benefit from specialist care 
in centres that see a large number of patients. Cohorting patients by organism is likely to be impractical 
in many hospitals in the absence of specific funding for this. Cohorting is also difficult to justify since our 
review did not identify a single confirmed case of new infection with P. aeruginosa acquired from a 
fellow patient with bronchiectasis. It is our judgement that there is currently not sufficient evidence to 
recommend separation of bronchiectasis patients with P. aeruginosa infection. Similarly, there are clear 
benefits of pulmonary rehabilitation with the evidence demonstrating improved exercise capacity, 
improved quality of life and reduced exacerbations.(9) These benefits outweigh the theoretical risk that 
attending a pulmonary rehabilitation class with other patients could expose the patient to the risk of 
transmission of a microorganism. Again, there is no evidence that pulmonary rehabilitation related 
transmission has occurred. Care for bronchiectasis in Europe is currently heterogeneous and 
predominantly inadequate with data suggesting most patients do not receive what may be regarded as 
the basic components of bronchiectasis care, such as access to chest physiotherapy, sputum culture, 
antibiotic therapy and self-management.(29) In this context, precious resources should be directed at 
improving basic medical management.  
Nevertheless, we suggest that patients with specific multi-drug and pan-drug resistant pathogens 
including M. abscessus and MRSA should be managed according to strict infection control procedures in 
the outpatient and inpatient setting. For all patients, care should be taken with aerosol generating 
procedures and we suggest that procedures such as sputum induction, chest physiotherapy or 
spirometry should be performed in separate and well ventilated rooms. 
In the event of suspected transmission or a suspected outbreak we recommend seeking expert 
microbiological help. Facilities to investigate potential outbreaks using molecular methods should be 
made available.  
We recommend that discussing the topic of infection control, including avoiding infections as well as the 
risk of transmission should be part of the bronchiectasis clinic consultation for all patients.  
For patient support groups, research initiatives and social events, the balance of risks and benefits must 
be carefully weighed on a case-by-case basis. The value to patients of participation in such events is 
clear, and the need for advocacy and support in a disease like bronchiectasis is acute. Therefore, in the 
absence of evidence of harm, we do not currently advocate preventing patients from participating in 
such activities. We nevertheless make the following recommendations: 
 Patients should be informed that contact with other patients may carry a risk of transmission of 
infection. This allows patients to make an informed decision about whether to participate in such 
events. 
 All participants at such events should practice rigorous hand hygiene measures. Patients should 
aim to minimise aerosols e.g. conduct chest clearance at home prior to attending and at events and 
cover their mouth while coughing.  
 Since shaking of hands is known to be a primary source of pathogen transmission in other areas, 
hand shaking at events is discouraged. 
 Venues should have adequate space and ventilation. 
 Basic infection control measures to reduce close contact between patients should be practiced 
e.g avoid sharing food/drinks/mobile phones and avoid activities promoting close physical contact.  
 Patients should not attend events with other patients if they are unwell, or have a current 
exacerbation. 
 We suggest that specific groups of patients are at higher risk from cross-infection e.g 
immunocompromised patients, or those with multidrug resistant organisms should discuss with their 
physician prior to attending events.   
 Where electronic or virtual means of communication (teleconferences, webinars etc) can be 
used, they should be used.  
 
Patients are also concerned to reduce their risk of exacerbation by reducing the acquisition of viral and 
other infections from patients. We identified no evidence that infection control measures can prevent 
exacerbations. We therefore suggest that patients are advised to practice standard hygiene measures, 
such as hand washing before meals and that patients should avoid contact where possible with children 
and adults with active viral infections. It was discussed that some patients in online forums recommend 
face-masks to reduce infection risk in bronchiectasis. The panel recommended against the use of 
facemasks due to a lack of evidence for their effectiveness and the risk of stigmatising bronchiectasis 
patients.  
Finally, the topic of cross-infection is a key research priority in bronchiectasis. Cross-infection was 
identified by both patients and physicians as one of the 55 key research questions in the field of 
bronchiectasis, In the EMBARC “roadmap” published in 2016.(17) We strongly recommend that large 
scale longitudinal studies are performed to ascertain the incidence and clinical implications of cross-
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